| Literature DB >> 26303855 |
Patrik Brundin1, Richard Wyse2.
Abstract
The results of a futility trial, which used the PPAR-γ receptor agonist pioglitazone in an attempt to modify disease progression in Parkinson disease, do not support initiation of further trials. However, although this trial was well designed and conducted, we question whether it is time to fully shut the door on pioglitazone.Entities:
Mesh：
Substances：
Year: 2015 PMID： 26303855 DOI： 10.1038/nrneurol.2015.150
Source DB: PubMed Journal: Nat Rev Neurol ISSN： 1759-4758 Impact factor: 42.937